Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 190

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 190
---
 they offer. The additional
burdens imposed upon broker-dealers by such requirements may discourage broker-dealers from recommending transactions in our securities,
which could severely limit the liquidity of our securities and consequently adversely affect the market price for our securities. In addition,
few broker or dealers are likely to undertake these compliance activities. Other risks associated with trading in penny stocks could also
be price fluctuations and the lack of a liquid market. See “Risk Factors” on page 5.

<div align='center'>LEGAL MATTERS</div>

The validity of the Common Stock offered hereby
will be passed upon by Aboudi Legal Group PLLC.

<div align='center'>EXPERTS</div>

The consolidated financial statements of Revium
RX as of December 31, 2024 and for the two years in the period ended December 31, 2024, included in this prospectus and in the registration
statement have been so included in reliance on the report of Ziv Haft, BDO member firm, an independent registered public accounting firm,
appearing elsewhere herein and in the Registration Statement.

<div align='center'>117

ADDITIONAL INFORMATION</div>

We have filed with the SEC this registration statement
on Form S-1 under the Securities Act with respect to the shares of Common Stock being offered by this Prospectus. This Prospectus, which
constitutes a part of this registration statement, does not contain all of the information in this registration statement and its exhibits.
For further information with respect to us and the Common Stock offered by this Prospectus, you should refer to this registration statement
and the exhibits filed as part of that document. Statements contained in this Prospectus as to the contents of any contract or any other
document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed
as an exhibit to this registration statement. Each of these statements is qualified in all respects by this reference.

Until we become subject to reporting requirements
under the Exchange Act, we will continue posting our annual, quarterly, and current reports through OTC Disclosure and News Services.
You may access and review the Company’s reports at OTC Markets’ website at https://www.otcmarkets.com/stock/RVRC/research.
You may also request a copy of these reports, at no cost, by writing or telephoning us at: Revium Rx., 10 HaMenofim Street, Herzliya,
Israel, telephone:1 800